m利用遗传相关性来优先考虑在2型糖尿病中重新使用的药物组
Astrid Johannesson Hjelholt1,2,3,4, Tahereh Gholipourshahraki1,5, Zhonghao Bai1
1Centre for Quantitative Genetics and Genomics, Aarhus University, Aarhus, Denmark.
The pharmacogenomics journal
|November 12, 2025
概括
本研究通过分析遗传数据和药物相互作用来确定2型糖尿病 (T2D) 的潜在新药标. 它强调了与T2D相关的特定药物类别和基因,有助于药物重新定位的努力.
科学领域:
- 遗传学 遗传学是一种遗传学.
- 药理学 药理学是指药理学的学科.
- 计算生物学 计算生物学
背景情况:
- 2型糖尿病 (T2D) 是一种复杂的多基因疾病,对健康有重大影响.
- 全基因组关联研究 (GWAS) 已经确定了众多T2D风险位置,但治疗翻译具有挑战性.
- 将遗传发现转化为有效的T2D疗法的有限成功需要新的方法.
研究的目的:
- 通过将遗传关联数据与药物-基因相互作用信息相结合,优先考虑2型糖尿病 (T2D) 的可用药物基因组.
- 确定新的治疗点,并促进对T2D的药物重新定位.
- 开发一种基因信息的管道,用于识别潜在的T2D治疗方法.
主要方法:
- 应用贝叶斯线性回归 (BLR) 多特征基因组模型来分析T2D的GWAS总结统计数据.
- 综合遗传数据与来自药物基因相互作用数据库 (DGIdb) 的药物基因相互作用数据.
- 药物组 (ATC第4级) 的计算后置包含概率 (PIP),以评估遗传相关性.
主要成果:
- 该模型成功验证了已知的抗糖尿病药物,证明了与T2D的强烈关联.
- 确定了对碳胺衍生物,纤维酸,尿酸抑制剂和免疫调节/抗菌剂的显著遗传相关性.
- 突出了关键的T2D相关基因 (例如,PPARG,KCNQ1,TNF,GCK) 并显示了贝扎菲布拉特与T2D位点的大量遗传重叠.
结论:
- 这项研究为T2D中药物重定位提供了一个新的,基因相关的管道.
- 贝扎菲布拉特是一种PPAR泛激动剂,由于其与T2D的遗传重叠,具有治疗代谢疾病的潜力.
- 这种方法可以加速对2型糖尿病的新治疗策略的识别.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Glucagon-like Receptor Agonists
828
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
828
Oral Hypoglycemic Agents: Biguanides and Glitazones
568
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
568
Genome-wide Association Studies-GWAS
15.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.3K
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Diabetes Mellitus: Overview and Type I Subtype
4.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K


